The factsheet has been successfully sent.
Please check your inbox.
Please fill in the form to receive the factsheet directly into your inbox

You have items in your inquiry list.
Inquire now?

20 January 2022 [Press release]

Demonstrated accuracy of GenoScreen™ SARS-CoV-2 RT-qPCR Assay for Omicron variant detection

As reported in our Application Notes #92007004, genomic or synthetic RNA from four VoCs was used to test the compatibility of GenoScreenTM SARS-CoV-2 RT-qPCR Assay towards SARS-CoV-2 variant detection. 1x104 copies RNA input was used and 6 replicates were performed in each experiment. The RT-qPCR assay was able to detect all 4 types of variants (including the Alpha, Beta, Gamma, and Delta variants). 100% detection status was attained among the 6 replicates. 

To further evaluate the detection efficiency against the Omicron variant, serial dilution of 1x105 copies down to 10 copies Omicron variant RNA input were tested. The RT-qPCR assay was able to detect all of the tested dilutions, therefore the detection sensitivity of the GenoScreenTM SARS-CoV-2 RT-qPCR Assay is not impacted by the Omicron variant.


About DiagCor

Headquartered in Hong Kong with ISO 13485 accredited Quality Management System, DiagCor has been dedicated solely to molecular diagnostics (MDx) since 2006. The global leader in flow-through hybridization technology, the company offers a range of products, solutions and services related to RNA and DNA analysis. As well as providing MDx laboratory services to Asia Pacific practitioners, DiagCor develops and manufactures MDx products and solutions, and offers MDx medical translation services and MDx consulting.

Press Contact

DiagCor Life Science

[email protected]